3 Reasons Exelixis, Inc. Could Excel in 2014

Exelixis has rallied strongly over the past 12 months, despite only having a single approved drug, which is only expected to generate $50 million in peak revenues. Can the stock continue soaring thanks to these 3 catalysts, and how does its future involve AstraZeneca, Johnson & Johnson, Medivation, and Roche?

Jan 16, 2014 at 6:30PM

Shares of Exelixis (NASDAQ:EXEL), a biotech company focused on small molecule treatments for cancer, have performed exceptionally well over the past 12 months, rallying more than 70% even though its one approved drug, Cometriq, is hardly expected to be a blockbuster.

Why has Exelixis, which once traded in the mid-$40s prior to the dot-com crash of 2000, suddenly generated so much bullish interest?

EXEL Chart

Source: YCharts.

Let's take a closer look at the company, how companies like AstraZeneca (NYSE:AZN), Johnson & Johnson (NYSE:JNJ), Medivation (NASDAQ:MDVN), and Roche (NASDAQOTH:RHHBY) could affect its future and three potential catalysts that could propel the stock to higher levels in 2014.

Exelixis in a nutshell
Exelixis' only marketed drug, Cometriq, was approved by the FDA in November 2012. The drug is approved to treat metastatic medullary thyroid cancer (MTC).

This was a major development because there are very few approved treatments that specifically that target that rare type of thyroid cancer -- traditional treatments consist of surgery followed by hormone therapy, radiation therapy, and chemotherapy.

Cometriq's only true competitor on the market is AstraZeneca's Caprelsa, a drug that was approved in the U.S. in 2011 and in Europe in 2012 for the same indication. Off-label competitors for metastatic MTC include Bayer and Amgen's Nexavar and Pfizer's Sutent.

Due to the rarity of MTC, which only accounts for 3% to 4% of all thyroid cancer cases in the United States, peak sales estimates of Cometriq are low at around $50 million. Between the commercial launch of Cometriq in January 2013 and the end of the third quarter on Sept. 30, 2013, Exelixis only reported $10.7 in revenues from the drug.

As expected, the company's financial condition is a bit precarious, with $279 million in cash being weighed down by $342 million in debt and a negative operating cash flow of $190 million.

Yet the stock has soared, giving it a lofty price-to-sales ratio of 41 and price-to-book ratio of 11. Why are investors willing to give Exelixis the benefit of the doubt and look past its lackluster sales growth and feverish fundamentals?

1. Additional approvals could unlock Cometriq's true value
The main thing to remember about Exelixis is that MTC was only expected to be the first of several approved indications. Here are the other main indications that the company is pursuing for the drug:




Prostate cancer

Previously treated, castration-resistant, metastatic or symptomatic

Phase 3, recruiting

Hepatocellular carcinoma

Previously treated

Phase 3, recruiting

Renal cell carcinoma

Previously treated

Phase 3, recruiting

Non-small cell lung cancer (NSCLC)

Advanced (stage IV)

Phase 2, active

Source: Company website.

With three major indications, especially prostate cancer, entering late-stage trials, Cometriq's growth potential cannot be ignored. If approved for the prostate cancer indication, analysts forecast that it could be an instant blockbuster, hitting peak sales of $1.6 billion.

The most compelling reason to believe that Cometriq can be approved is the fact that phase 2 data showed a median overall survival rate of 10.8 months in a population where 73% of the patients had two or more prior therapies.

While this can't match the 18.4 months that Medivation/Astellas' Xtandi has accomplished or the 15.8 months claimed by Johnson & Johnson's Zytiga, it's still enough to warrant a possible FDA approval.

There are two main reasons that it could be approved:

  • There aren't that many late-stage prostate cancer treatments on the market -- the majority of the market has been split between three major drugs -- Xtandi, Zytiga, and Dendreon's Provenge.

  • According to its COMET-1 and COMET-2 phase 3 trials, Exelixis is testing the treatment only on patients who have failed a treatment with Zytiga, Xtandi, or Sanofi's chemotherapy drug Taxotere -- which means it might not have to compete at all against the dominant treatments.

Top-line data from both COMET trials are expected later this year -- which would be a major near-term catalyst for the stock.

Meanwhile, additional approvals of hepatocellular carcinoma and renal cell carcinoma could further solidify Cometriq's blockbuster status.

2. A possible European approval in 2014
Although Exelixis' current market of metastatic MTC in the U.S. is small, a possible approval in Europe could easily double Cometriq sales.

So far, things look good -- last month, Exelixis announced that the European Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion regarding its marketing authorization application (MAA) for Cometriq for the same metastatic MTC indication.

If approved by the European Commission, Cometriq should be commercialized quickly, thanks to a previously signed commercialization agreement with Swedish Orphan Biovitrum (Sobi) in 2013.

Most importantly, an approval in Europe would help Cometriq gain ground against Caprelsa, which only generated $27 million in sales in fiscal 2012.

3. Major pharmaceutical collaborators
The last major catalyst for Exelixis is its strength in major pharmaceutical collaborations.

Its first main drug beyond Cometriq is GDC-0973 (XL518), a drug which is being developed by Roche's Genentech unit under a collaboration agreement with Exelixis. Exelixis handled the drug through the end of phase 1 trials, after which it was transferred over to Genentech.

XL518 is a signalling pathway inhibitor which could have multiple applications in a variety of cancers. The drug is being tested first in a phase 3 trial as a late-stage skin cancer treatment in combination with Roche's Zelboraf.

If approved, Exelixis is entitled to 50% of the profits from the first $200 million in U.S. sales and 30% of the profits from U.S. sales up to $400 million. Exelixis is also entitled to low double-digit royalties on overseas sales.

In addition to Roche, Exelixis holds partnerships in compounds manufacturing with GlaxoSmithKline, Sanofi, Daiichi-Sankyo, Bristol-Myers Squibb, and Merck.


Source: Company website.

Together, these collaborations have the potential to yield milestone payments of up to $2.4 billion.

Exelixis anticipates 10%, 41%, and 49% of those payments to respectively come from clinical development, regulatory, and commercial milestones. Those payments could support the top line for Exelixis, which has only generated $27 million in revenue in the first three quarters of 2013.

More importantly, the backing of all these major companies bodes well for a smaller biotech company like Exelixis.

The Foolish takeaway
In closing, Exelixis is a risky stock with lots of upside potential if Cometriq is approved for additional indications beyond metastatic MTC. However, the company's financial position is a bit shaky, and could lead to additional share-diluting stock offerings.

For now, good news about its prostate cancer progress and an approval in Europe could cause the stock to rally in the near term. Meanwhile, Exelixis' collaborations with major pharmaceutical companies should provide it with a small cash cushion if times get tough.


Want to learn more about the health-care industry and Obamacare?
Obamacare seems complex, but it doesn't have to be. In only minutes, you can learn the critical facts you need to know in a special free report called "Everything You Need to Know About Obamacare." This FREE guide contains the key information and money-making advice that every American must know. Please click here to access your free copy.


Fool contributor Leo Sun has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Exelixis and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers